Promising drug could save lives in rare, deadly lung disease
NCT ID NCT07631208
First seen Jun 13, 2026 · Last updated Jun 17, 2026 · Updated 1 time
Summary
This study tests a drug called teclistamab in 24 adults with a severe, rapidly worsening lung disease linked to anti-MDA5 antibodies. The disease has a very poor outlook, with only about 25% of patients surviving 90 days without a lung transplant. Teclistamab aims to improve survival by targeting immune cells that drive the disease. The main goal is to see if more patients can survive without needing a lung transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE RAPIDLY PROGRESSIVE INTERSTITIAL LUNG DISEASE ASSOCIATED WITH ANTI-MDA5 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.